We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Hemometer Compared with Hematology Analyzer

By LabMedica International staff writers
Posted on 18 Apr 2019
The burden of anemia remains unacceptably high in sub-Saharan Africa. More...
It is linked to numerous life-threatening consequences like poor cognitive ability, diminished immunity and aggravated mortality.

To avert its effect, timely and accurate determination of hemoglobin concentration has been recognized. This has taken varied determination methods such as cyanmethemoglobin, use of copper II sulfate, automated hematology analyzers and point-of-care (POC) devices as the latest invention.

Medial Laboratory Scientists at Clarke International University (Kampala, Uganda) and their colleagues enrolled 402 participants, of these, 156 (38.8%) were male and 246 (61.2%) female. Participants had varied age categories, of whom 65 (16.2%) were 1 month–5 years, 42 (10.4%) were 5–11 years, 12 (3.0%) were 12–14 years, while 283 (70.4%) were 15 years and older. The average levels of Hb were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic participants, respectively.

Blood samples were assayed to estimate the hemoglobin (Hb) concentration using the TrueHb hemometer and Sysmex i3 hematology analyzer. Anemia was defined as Hb levels less than 11.0 g/dL, 11.5 g/dL and 12.0 g/dL for children aged 6–59 months, 5–11 years and 12–14 years, respectively. For adults, anemia was considered as Hb concentration less than 12.0 g/dL in non-pregnant women, 11.0 g/dL in pregnant women and 13.0 g/dL in males.

The team reported that the average Hb levels were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic patients, respectively. They found that 155 participants were anemic, giving an anemia prevalence of 38.6%. The mean difference of the TrueHb and Sysmex i3 assays was 2.222 ± 1.079, and the two devices did not show a difference in their measurements. Further, they showed a significant level of agreement and intraclass correlation coefficients. The sensitivity, specificity, positive and negative predictive values were 100 %, 51.01%, 55.16% and 100 %, respectively. The average performance turnaround time (TAT) for the TrueHb hemometer was 2.46 minutes.

The authors concluded that the TrueHb POC hemometer is an accurate POC for Hb estimation with a good performance agreement with the Sysmex i3 analyzer. This, coupled with its utility aspects, makes it a good diagnostic tool in a high anemia burden and low-resource setting. The study was published on April 1, 2019, in the Journal of Blood Medicine.

Related Links:
Clarke International University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.